Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.11, read 2026-11-05
Ethical passes the values gate
Price69.57 USD
Fair value75.00
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation57.22+21.6% to today ✓Markup gives way to Accumulation after an 8% rise in 13 weeks
2026-07-02Read Markup53.13+30.9% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Exelixis Inc holds its Markup at $69.57. The statistical read favours the buyers, held for 16 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 16 days
Price at the screen
$69.57
Valuation
20.83 trailing · 16.28 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.42
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.08%
Below 33%
Interest-bearing debt is just 6.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.27%
Below 33%
Cash held in interest-bearing accounts and securities is 20.3% of assets, under the one-third limit.
Pass
Receivables
27.05%
Below 49%
Money owed to the company is 27.0% of assets, under the 49% limit.
Pass
Revenue purity
2.98%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Exelixis clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 6%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EXEL's ethical verdict changes
Today EXEL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 7% discount to our $75.00 fair value, narrow competitive moat, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 7.2% discount to the base estimate.
Where our models see it going: fair-value estimate $75.00, with a range of $70.53 to $117.55, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
One cancer drug carries a whole biotech
A single approved pill for tough kidney cancers keeps the cash flowing at Exelixis. The business posts a 35 percent profit margin and 41 percent return on equity while revenue edges up 10 percent a year. Forward earnings sit at just 14 times and the ethical screen clears without issue, so the numbers look solid on paper.
Yet the narrow moat leaves little room for error if competition arrives or regulators shift the goalposts. Our own fair value sits only 11 percent above the current price, the opportunity rating stays at none, and fifteen analysts cluster around a $50 target that sits below where the shares trade today.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EXEL trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$72.75+9.8%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49.
2026-10-29Accumulation$66.28+2.7%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$64.53+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$64.53+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$64.53+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$64.53+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$64.53+2.7%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$62.83+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$62.83+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$62.83+5.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
